Home Markets Moderna asks FDA to approve Omicron Covid boosters for children as young as 6 years old

Moderna asks FDA to approve Omicron Covid boosters for children as young as 6 years old

by SuperiorInvest

Following CDC approval to vaccinate children ages 6 months to 5 years, 4-year-old Eleanor Kahn sits with her father, Alex, as nurse Jillian Mercer administers Moderna’s coronavirus disease (COVID-19) vaccine at Rady Children’s Hospital in San Diego. , California, USA, 21 June 2022.

Mike Blake | Reuters

modern The company announced Friday that it has asked the Food and Drug Administration to approve its Omicron boosters for children.

Moderna filed two separate applications for FDA approval, one for adolescents ages 12 to 17 and the other for children ages 6 to 11. The Boston-based biotech company said it will also ask the FDA to grant approval for the youngest children, ages 6 months to 5 years. -old, later this year.

The Centers for Disease Control and Prevention said in a document released Tuesday that it expects children to be eligible for Omicron boosters by mid-October, pending FDA approval. The CDC’s Vaccine Advisory Committee has meetings scheduled for October 19 and 20.

Pfizer told a CDC advisory committee earlier this month that he expects to ask the FDA in early October to authorize omicron boosters for children ages 5 to 11.

US health regulators cleaned omicron boosters Moderna for adults earlier this month. Pfizer boosters have been approved for persons 12 years of age and older.

The new shots target the omicron BA.5 subvariant as well as the original strain of Covid that first appeared in China in late 2019. The FDA and CDC expect the new boosters to provide superior protection against infection and disease because they target the most common omicrons. subvariant.

The old vaccines that were designed to fight the original strain of Covid no longer provide meaningful protection against infection and mild disease because the virus has mutated so much. There is also concern that the effectiveness of the original injections in preventing hospitalization and serious illness is beginning to decline.

Public health officials are confident about the new Omicron BA.5 boosters, although it’s unclear how effective they will be in the real world. The injections were approved without data from human clinical trials

CNBC Health and Science

Read CNBC’s latest global health news:

Source Link

Related Posts

%d bloggers like this: